Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Talecris Biotherapeutics Holdings Corp. (TLCR) Create: Alert

All | News | Filings
Date FiledTypeDescription
06/06/2011 8-K Quarterly results
05/04/2011 8-K Submission of Matters to a Vote of Security Holders
05/02/2011 8-K Form 8-K - Current report
04/27/2011 8-K Form 8-K - Current report
03/04/2011 8-K Other Events, Financial Statements and Exhibits
Docs: "Grifols and Talecris Announce the Outside Date of their Merger Agreement has been Extended to June 30, 2011"
02/23/2011 8-K Form 8-K - Current report
02/17/2011 8-K Form 8-K - Current report
02/11/2011 8-K Form 8-K - Current report
02/04/2011 8-K Other Events
12/14/2010 8-K Form 8-K - Current report
10/28/2010 8-K Form 8-K - Current report
08/12/2010 8-K Form 8-K - Current report
08/09/2010 8-K Other Events, Financial Statements and Exhibits
Docs: "Talecris Biotherapeutics and Grifols S.A. Receive FTC Request for Additional Information Regarding Proposed Merger"
07/29/2010 8-K Quarterly results
Docs: "Talecris Biotherapeutics Announces Second Quarter 2010 Financial Results - Second Quarter 2010 Revenue Increases 7.3% to $402.8 Million - - Gross Margin Improves to 44.6% - - Reports Diluted EPS of $0.37 -"
07/19/2010 8-K Other Events
07/14/2010 8-K Other Events, Financial Statements and Exhibits
Docs: "Talecris Biotherapeutics Announces Premerger HSR Filing Research Triangle Park, NC - Talecris Biotherapeutics Holdings Corp. today confirmed that it filed its premerger notification and report form with respect to its proposed merger with Grifols S.A. under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 with the Federal Trade Commission and the Antitrust Division of the U.S. Department of Justice on July 6, 2010. Grifols has informed Talecris that their company filed its premerger notification and report form the following day."
06/10/2010 8-K Form 8-K - Current report
06/08/2010 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Letter Agreement, effective as of June 6, 2010, amending the terms of a certain Employment Agreement, as subsequently amended and restated on October 10, 2008, by and between the Company and John M. Hanson",
"Letter Agreement, effective as of June 4, 2010, amending the terms of a certain Employment Agreement, as subsequently amended and restated on September 5, 2008 and November 6, 2008, by and between the Company and John F. Gaither, Jr"
06/07/2010 8-K Form 8-K - Current report
06/03/2010 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Letter Agreement, amending the terms of a certain Employment Letter, as subsequently amended on December 19, 2008, by and between the Company and John R. Perkins",
"Separation Pay Agreement, amending the terms of a certain Employment Letter, as subsequently amended on December 19, 2008, by and between the Company and John R. Perkins"
04/28/2010 8-K Quarterly results
Docs: "Talecris Biotherapeutics Announces First Quarter 2010 Results - First Quarter 2010 Revenue Increases to $381.0 Million - - Net Income Increases 35.6% to $45.3 Million - -Reports Diluted EPS of $0.35-"
04/22/2010 8-K Submission of Matters to a Vote of Security Holders
02/23/2010 8-K Form 8-K - Current report
02/11/2010 8-K Form 8-K - Current report
12/17/2009 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Dean Mitchell Appointed to Talecris Board of Directors"
11/09/2009 8-K Quarterly results
Docs: "Talecris Biotherapeutics Announces Third Quarter 2009 Results - Posts Diluted EPS of $0.38, representing growth of 72.7% Year-over-Year - - Gross Margin Improves 210bps Year-over-Year to Reach 41.7% - - Provides Full Year 2009 Financial Outlook -"
10/21/2009 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
Docs: "Indenture among Talecris Biotherapeutics Holdings Corp., the Guarantors named therein, and The Bank of New York Mellon Trust Company, N.A. (including Form of 7.75% Note due 2016 attached as Exhibit A)",
"Registration Rights Agreement among Talecris Biotherapeutics Holdings Corp., Morgan Stanley & Co. Incorporated, Goldman, Sachs & Co., Wells Fargo Securities, LLC, Citigroup Global Markets Inc., and the Guarantors named therein"
10/16/2009 8-K Other Events, Financial Statements and Exhibits
Docs: "Talecris Biotherapeutics Announces Pricing of $600 Million Senior Notes due 2016"
10/16/2009 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
Docs: "First Amendment to Revolving Credit Agreement, by and among Talecris Biotherapeutics Holdings Corp., Wachovia Bank, National Association, Wells Fargo Foothill, Inc., and other signatories thereto"
10/13/2009 8-K Other Events, Financial Statements and Exhibits
Docs: "Talecris Biotherapeutics Announces Private Offering of $550 Million Senior Notes due 2016"
10/13/2009 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy